LATENT TECH

GENFI · FORENSICS

INDEX/$BMGL · 2026-09-14

$BMGL

$4.5800−4.18%

Basel Medical Group · NasdaqCM · mkt cap $7.17M · cash $1.04M (Dec 31, 2025 unaud.) · O/S ~1,565,480 ordinary post 1-for-12 (6-K 2026-06-10); CONFLICT vs vendor 18.8M pre-split

Cutoff 2026-09-14 09:30 ET

NO-ISSUER-CATALYST / MICROFLOAT TAPE

RATINGS

  • OVERALLHIGH
  • OVERHEADLOW→MED
  • DILUTIONMED
  • DIL. FREQLOW
  • OFFERINGMED
  • CASH NEEDHIGH
  • COMPLIANCELOW
  • BANKERHIGH

VIEW

Loading pack…

THREE FINDINGS

  1. 01No issuer catalyst into microfloat melt-up

    Zero EDGAR acceptances in 96h. Partial pre-market ~5.18M sh / $35.6M to ~$8.12 (+77%) on ~1.57M O/S — ~3.3× the share count. Board 6-K is Sep 2.

  2. 02Post-split O/S conflict + unregistered paper rule

    Anchor ~1,565,480 ordinary (6-K Jun 10); vendor 18.8M pre-split/stale. UW warrants ~10.6k @ $60 unregistered/OTM ≠ free float. No ATM/S-3.

  3. 03Recycled 2025 narratives fail catalyst-age test

    BTC $1B (on hold Jul 2025), Pancare S$375M, lock-up waiver, Bethesda — all 2025. Analogs: 5/5 same-ticker no-news megavol closed D+1 red; median D+3 -20%. Banker D.

SUPPLY

O/S

~1.57M post 1-for-12

Control

Rainforest ~54%

UW warrants

~10.6k @ $60 ≠ float

ATM/converts

none on file

COMPLIANCE CLOCK

  1. 2026-07-10

    Bid cured

    5550(a)(2) regained after 1-for-12; basis $4.58

  2. ongoing

    Equity standard

    ~$5.04M SE vs $2.5M on face; GC on shareholder support

  3. n/a

    MVLS $35M

    mcap $7.17M; not governing if equity holds — no notice found

  4. ongoing

    Class action

    NY multi-issuer suit filed Jul 23, 2026; early stage

NEXT WATCH

  • Any F-1/PP after 2025 lock-up waiver
  • Class-action procedural updates (Aug 6-K suit)
  • Cash/GC / related-party support disclosures
  • Same-ticker fade vs hold after no-news megavolume
  • Nasdaq equity buffer / MVLS if equity slips

Internal research only — not investment advice. NOT a retail broker. Cutoff 2026-09-14 09:30 ET. Source files: HTML dossier, 1-pager, social pack, and PDF linked in VIEW. Do not treat this console as a solicitation or an offer to buy or sell securities.